Follow-up survey of nivolumab, pembrolizumab and ipilimumab in Sapporo City General Hospital
Not Applicable
- Conditions
- on-small-cell lung cancer, malignant melanoma, head and neck cancer, gastric cancer, renal cell cancer, urothelial carcinoma, Hodgkin lymphoma
- Registration Number
- JPRN-UMIN000034302
- Lead Sponsor
- Sapporo City General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
Not provided
Exclusion Criteria
The case that the dosage situation and side effect information of nivolumab, pembrolizumab or ipilimumab cannot confirm from a medical record enough
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immune-related adverse events
- Secondary Outcome Measures
Name Time Method Response rate, Overall survival